{
  "id": "nclex_ngn_mm_2026_001",
  "questionType": "matrixMatch",
  "stem": "The nurse is reviewing the electronic health record (EHR) and new provider orders for a client in the emergency department. For each potential nursing action, determine if it is an 'Indicated Action' or a 'Contraindicated Action' based on the comprehensive client data provided.",
  "tabs": [
    {
      "title": "Nurses' Note",
      "content": "A 68-year-old male with a history of end-stage renal disease (ESRD) on hemodialysis, heart failure (HF), and type 2 diabetes mellitus presents to the emergency department with complaints of profound muscle weakness, nausea, and 'feeling fuzzy'. The client reports missing his scheduled dialysis session yesterday because he 'couldn't arrange for a ride'. He appears lethargic but is oriented to person and place. He denies chest pain but reports palpitations."
    },
    {
      "title": "Vital Signs",
      "content": [
        {
          "time": "1400",
          "HR": "75",
          "BP": "132/78",
          "RR": "18",
          "SpO2": "96% on room air",
          "Temp": "37.1°C (98.8°F)"
        },
        {
          "time": "1430",
          "HR": "64",
          "BP": "120/74",
          "RR": "18",
          "SpO2": "95% on room air",
          "Temp": "N/A"
        },
        {
          "time": "1500",
          "HR": "54",
          "BP": "105/66",
          "RR": "16",
          "SpO2": "95% on room air",
          "Temp": "N/A"
        }
      ]
    },
    {
      "title": "Laboratory Results",
      "content": [
        {
          "lab": "Potassium",
          "value": "7.2 mEq/L",
          "reference": "3.5-5.0 mEq/L"
        },
        {
          "lab": "Creatinine",
          "value": "8.9 mg/dL",
          "reference": "0.6-1.2 mg/dL"
        },
        {
          "lab": "BUN",
          "value": "95 mg/dL",
          "reference": "7-20 mg/dL"
        },
        {
          "lab": "Glucose, Random",
          "value": "140 mg/dL",
          "reference": "70-140 mg/dL"
        },
        {
          "lab": "Digoxin Level",
          "value": "1.8 ng/mL",
          "reference": "0.8-2.0 ng/mL"
        },
        {
          "lab": "Troponin I",
          "value": "<0.01 ng/mL",
          "reference": "<0.04 ng/mL"
        }
      ]
    },
    {
      "title": "Diagnostics",
      "content": "12-Lead ECG Interpretation: Sinus bradycardia at 55 bpm. PR interval prolonged at 0.24 seconds. Tall, peaked T waves noted in precordial leads. QRS duration 0.10 seconds. No acute ST-segment elevation or depression."
    },
    {
      "title": "Medication Administration Record",
      "content": {
        "homeMedications": [
          "Digoxin 0.125 mg PO daily",
          "Lisinopril 10 mg PO daily",
          "Furosemide 40 mg PO daily",
          "Metformin 500 mg PO BID"
        ],
        "newEDOrders": [
          "Calcium gluconate 1 gram IV over 5 minutes STAT",
          "Regular insulin 10 units IV push STAT",
          "Dextrose 50% 50 mL IV push STAT",
          "Sodium polystyrene sulfonate 15 grams PO STAT",
          "Prepare for emergent hemodialysis"
        ]
      }
    }
  ],
  "rows": [
    "Administer calcium gluconate 1 gram IV.",
    "Administer regular insulin 10 units IV push with Dextrose 50%.",
    "Administer sodium polystyrene sulfonate 15 grams PO.",
    "Administer the client's scheduled home dose of digoxin.",
    "Prepare the client for emergent hemodialysis."
  ],
  "columns": [
    "Indicated Action",
    "Contraindicated Action"
  ],
  "answer": [
    [
      "Administer calcium gluconate 1 gram IV.",
      "Contraindicated Action"
    ],
    [
      "Administer regular insulin 10 units IV push with Dextrose 50%.",
      "Indicated Action"
    ],
    [
      "Administer sodium polystyrene sulfonate 15 grams PO.",
      "Indicated Action"
    ],
    [
      "Administer the client's scheduled home dose of digoxin.",
      "Contraindicated Action"
    ],
    [
      "Prepare the client for emergent hemodialysis.",
      "Indicated Action"
    ]
  ],
  "rationale": {
    "correct": "The nurse must recognize the life-threatening contraindication of administering IV calcium to a client with suspected digoxin toxicity. The combination of hyperkalemia, renal failure, bradycardia, a prolonged PR interval, and a high-therapeutic digoxin level creates a 'perfect storm' where IV calcium can potentiate digoxin's effect on the myocardium, leading to fatal dysrhythmias such as complete heart block or ventricular tachycardia. This is a critical 'SAFETY STOP' moment where the nurse must withhold the medication and immediately notify the provider. \n\n**Pathophysiology:** Digoxin inhibits the Na+/K+-ATPase pump in myocardial cells, leading to increased intracellular sodium and calcium. Hyperkalemia also reduces the activity of this pump. Calcium gluconate further increases extracellular calcium, exacerbating the intracellular calcium overload caused by digoxin. This synergistic effect can trigger fatal arrhythmias.\n\n**Clinical Pearl:** Always assess for signs of digoxin toxicity (e.g., bradycardia, AV block, nausea, vomiting, altered mental status) and review digoxin levels before administering calcium to hyperkalemic patients, especially those with renal impairment.",
    "incorrect": "Failing to identify the contraindication for calcium gluconate administration places the client at immediate risk of death. Proceeding with standard hyperkalemia protocol without synthesizing all data points (MAR, Labs, ECG, Vitals) demonstrates a failure in clinical judgment and risk identification. Similarly, administering another dose of digoxin would worsen the existing toxicity. The other actions (insulin/dextrose, SPS, dialysis) are appropriate and necessary components of care.\n\n**Pathophysiology:** Insulin shifts potassium into cells by stimulating the Na+/K+-ATPase pump. SPS exchanges sodium for potassium in the gut, promoting potassium excretion. Hemodialysis removes potassium directly from the bloodstream.\n\n**Clinical Pearl:** Remember the mnemonic 'C BIG K Drop' for hyperkalemia treatment: Calcium, Bicarbonate, Insulin, Glucose, Kayexalate (SPS), Dialysis. However, always consider contraindications and patient-specific factors.",
    "answerBreakdown": [
      {
        "label": "Administer calcium gluconate 1 gram IV.",
        "content": "This is a CONTRAINDICATED ACTION. While calcium gluconate is standard for stabilizing the cardiac membrane in hyperkalemia, it is extremely dangerous in patients with digoxin toxicity. This client has multiple signs: bradycardia (HR 54), first-degree AV block (PR 0.24 sec), and a high-therapeutic digoxin level (1.8 ng/mL). IV calcium acts synergistically with digoxin on the Na-K-ATPase pump, increasing intracellular calcium and markedly increasing the risk of fatal cardiac arrest.\n\n**Pathophysiology:** Digoxin and calcium both increase intracellular calcium concentrations in cardiac myocytes. When combined, this effect is amplified, leading to increased myocardial contractility and potentially fatal arrhythmias.\n\n**Clinical Pearl:** In suspected digoxin toxicity, focus on alternative hyperkalemia treatments like insulin/dextrose and sodium polystyrene sulfonate. Digoxin-specific antibody fragments (Digibind) may be necessary in severe cases.",
        "isCorrect": true
      },
      {
        "label": "Administer regular insulin 10 units IV push with Dextrose 50%.",
        "content": "This is an INDICATED ACTION. Insulin is a primary, rapid-acting intervention to treat hyperkalemia by shifting potassium from the extracellular to the intracellular space. Because the client's glucose is 140 mg/dL, administering dextrose concurrently is essential to prevent iatrogenic hypoglycemia.\n\n**Pathophysiology:** Insulin stimulates the Na+/K+-ATPase pump in skeletal muscle and liver cells, promoting potassium uptake into these cells. Dextrose is given to prevent hypoglycemia, as insulin drives glucose into cells along with potassium.\n\n**Clinical Pearl:** Monitor blood glucose levels closely after insulin administration, as hypoglycemia can occur rapidly.",
        "isCorrect": true
      },
      {
        "label": "Administer sodium polystyrene sulfonate 15 grams PO.",
        "content": "This is an INDICATED ACTION. This cation-exchange resin works in the gastrointestinal tract to bind potassium and excrete it from the body. While it has a slower onset than insulin, it is a crucial component for removing total body potassium and is part of the standard treatment protocol.\n\n**Pathophysiology:** Sodium polystyrene sulfonate (SPS) exchanges sodium ions for potassium ions in the large intestine. The potassium-bound resin is then excreted in the feces, reducing the overall potassium load in the body.\n\n**Clinical Pearl:** Be aware that SPS can cause constipation or fecal impaction. Ensure adequate bowel function and consider administering a stool softener concurrently.",
        "isCorrect": true
      },
      {
        "label": "Administer the client's scheduled home dose of digoxin.",
        "content": "This is a CONTRAINDICATED ACTION. The client is already exhibiting clinical and ECG signs of digoxin toxicity (bradycardia, prolonged PR interval) with a digoxin level at the upper limit of the therapeutic range. Administering another dose would be a serious medication error and would worsen the existing toxicity, especially given his acute-on-chronic renal failure, which impairs digoxin clearance.\n\n**Pathophysiology:** Renal failure impairs digoxin excretion, leading to drug accumulation and increased risk of toxicity. The client's bradycardia and prolonged PR interval are indicative of digoxin's effect on the AV node, slowing conduction.\n\n**Clinical Pearl:** In patients with renal impairment, digoxin doses should be reduced, and serum levels should be monitored closely. Hold digoxin and notify the provider immediately if signs of toxicity are present.",
        "isCorrect": true
      },
      {
        "label": "Prepare the client for emergent hemodialysis.",
        "content": "This is an INDICATED ACTION. For a client with ESRD who missed a session and now presents with severe, life-threatening hyperkalemia (K+ 7.2) with cardiotoxic effects, emergent hemodialysis is the definitive and most effective treatment to remove potassium from the body and correct the metabolic disturbances.\n\n**Pathophysiology:** Hemodialysis uses a semipermeable membrane to filter blood, removing excess electrolytes (including potassium), waste products (creatinine, BUN), and fluid. It is the most rapid and effective method for lowering potassium levels in patients with renal failure.\n\n**Clinical Pearl:** Ensure vascular access is patent and ready for hemodialysis. Monitor vital signs closely during the procedure, as rapid electrolyte shifts can cause hypotension and arrhythmias.",
        "isCorrect": true
      }
    ]
  },
  "pedagogy": {
    "bloomLevel": "Analyzing",
    "cjmmStep": "Take Actions",
    "nclexCategory": "Reduction of Risk Potential",
    "nclexSubcategory": "Potential for Complications of Diagnostic Tests/Treatments/Procedures",
    "difficulty": "Hard",
    "topicTags": [
      "Hyperkalemia",
      "Digoxin Toxicity",
      "Medication Safety",
      "Contraindication",
      "Chronic Kidney Disease",
      "Pharmacology",
      "ECG Interpretation"
    ]
  },
  "sentinelStatus": "healed_v2026_v8"
}